A study conducted by Jankowska et al. suggested EZH2 mutations were early events in malignant evolution as they were detected in patients with CMML-1, the prognostically favorable CMML subgroup [58]. This evidence concerns the gene EZH2 and chronic myelomonocytic leukemia.